

Oct 11 1999

## REMARKS

The Examiner withdrew the telephonic restriction requirement of 30 April 1998 and issued a new restriction requirement. The Examiner classified the claims as follows: Group I (claims 1-5) drawn to a method of identifying and isolating nucleic acids encoding T-cell receptors (TCR) specific for tumor associated antigen (TAA) using a transgenic non-human vertebrate; Group II (claims 6-19) drawn to nucleic acids and recombinant cells; Group III (claim 3) drawn to a method of identifying TAA's; and Group IV (claim 21) drawn to a method of gene therapy.


Applicants hereby elect to prosecute Group I (claims 1-5) with traverse. Applicants expressly reserve their right under 35 U.S.C. § 121 to file a divisional application directed to the nonelected subject matter during the pendency of this application, or an application claiming priority from this application. Applicants request examination of the elected subject matter on the merits.

No new matter has been added and entry of the amendment is respectfully requested. In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 313332000100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

OCT 08 1999

Dated: October 8, 1999

  
Suzannah K. Sundby  
Registration No. 43,172

Morrison & Foerster LLP  
2000 Pennsylvania Avenue, N.W.  
Washington, D.C. 20006-1888  
Telephone: (202) 887-1687  
Facsimile: (202) 785-7619